NEW ORLEANS -- Brexpiprazole (Rexulti) helped ease agitation in people with Alzheimer's dementia, according to a phase III study. Over the course of the 12-week trial, patients on either a 2-mg or ...
These data represent one of the largest clinical development programs to date for adults living with PTSD and a significant development in a therapy area that hasn’t seen a new approval for a ...
A combination of brexpiprazole (Rexulti) and sertraline improved post-traumatic stress disorder (PTSD) symptoms more than sertraline alone, a phase III trial found. The primary endpoint was the change ...
SAN FRANCISCO--(BUSINESS WIRE)--Otsuka America Pharmaceutical, Inc., (Otsuka) and Lundbeck US (Lundbeck) today presented positive efficacy and safety data from multiple Phase 3 studies of ...
Credit: Getty Images. The sNDA is supported by data from two phase 3 studies that evaluated the efficacy and safety of brexpiprazole in patients with agitation associated with Alzheimer dementia. The ...
The Food and Drug Administration has given Lupin tentative approval for brexpiprazole tablets, in dosage strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. The medication is a generic of Otsuka ...
Credit: Getty Images. If approved, brexpiprazole would be the first medication indicated for AAD in the US. The Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback